ETFs ICON Public Limited Company

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-22 pm EST			5-day change	1st Jan Change
203.07 ^USD	-0.98%		+1.80%	-3.17%

Jan. 14	ICON Public Limited Company Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 03:45 PM
Jan. 14	ICON Reaffirms 2024 Outlook, Provides 2025 Guidance; Shares Down Pre-Bell	MT

ETFs positioned on ICON Public Limited Company

Name	Weight	AuM	1st Jan change	Investor Rating
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD	3.68%	0 M€	-.--%
BMO MSCI INNOVATION INDEX ETF - CAD	1.28%	0 M€	-.--%	-
FIRST TRUST IPOX EUROPE EQUITY OPPORTUNITIES ETF - DISTRIBUTING - USD	0.91%	4 M€	+7.41%
LYXOR NET ZERO 2050 S&P WORLD CLIMATE PAB (DR) UCITS ETF - ACC - USD	0.12%	0 M€	-.--%
DEMOCRACY INTERNATIONAL FUND ETF - USD	0.12%	8 M€	+3.03%	-
LEVERAGE SHARES PLC - 3X LONG TOTAL WORLD ETP	0.03%	0 M€	-.--%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	0.02%	578 M€	+1.74%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.02%	49 M€	+2.27%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - ACC - EUR	0.02%	438 M€	+1.52%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.02%	55 M€	+1.76%	-
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.01%	27 M€	+1.12%	-
IQ REAL RETURN ETF - USD	0.01%	0 M€	+3.89%
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF ACC - EUR	0.01%	131 M€	+0.86%	-
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.01%	9 M€	+0.63%	-
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF ACC - EUR	0.01%	67 M€	+0.61%	-

ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.

Employees

42,250

Sector

Biotechnology & Medical Research

Calendar

2025-02-18 - Q4 2024 Earnings Release (Projected)

More about the company